Litigation Details for Sanofi-Aventis U.S. LLC v. Apotex Corp. (D. Del. 2020)
✉ Email this page to a colleague
Sanofi-Aventis U.S. LLC v. Apotex Corp. (D. Del. 2020)
| Docket | ⤷ Try a Trial | Date Filed | 2020-06-12 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 10,583,110; 8,008,003; 8,013,002; 9,000,002 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Sanofi-Aventis U.S. LLC v. Apotex Corp.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Biologic Drugs cited in Sanofi-Aventis U.S. LLC v. Apotex Corp.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Sanofi-Aventis U.S. LLC v. Apotex Corp. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-09-09 | 107 | Claim Construction Chart | Chart for U.S. Patent Nos. 10,583,110 (“the ’110 patent”) and 10,716,777 (“the ’777 patent”). The…the ’110 patent. Exhibit B to the Joint Claim Construction Chart is a copy of the ’777 patent. Exhibit… ’110 Patent, Figs. 1-5 ’777 patent, Exhibit B, including…110 Patent at 2:43-3:41 Prosecution file history of the ’110 patent, … Prosecution file history of the ’777 patent, ’110 Patent at 8:61-65 Exhibit D | External link to document |
| 2020-11-02 | 143 | Redacted Document | Count I: Infringement of U.S. Patent No. 10,583,110 (“’110 patent”) under 35 U.S.C. § 271…IV (“’592 patent”) prostate cancer with cabazitaxel 10,583,110 …Orange Book-listed patents, including the ’170 patent and ’907 patent. Ex. 15, Patent Cert. Pursuant to…110 patent under 35 U.S.C. § 271(b); • Count III: Infringement of U.S. Patent No. …of Sanofi as to the ’170 patent, but vacated the judgment on the ’592 patent for the disclaimed claims | External link to document |
| 2021-08-30 | 248 | Exhibits A-D | 7 0.2 9 0.2 Pyrexia … Patent Owner's Response as submitted in U.S. Patent and Trade Patent and Trademark…United States Patent (10) Patent No.: … United States Patent ( 10 ) Patent No.: US 10,583,110… Patent and Trademark Office before the Patent Trial and Appeal | External link to document |
| 2022-04-15 | 269 | Exhibit to a Document | Fatigue 77(35.8) 8( 3.7) Vomiting …respect to Patent Owner’s MTA, and Patent Owner filed a Response (Paper 90). 3 Patent Owner …prosecution of U.S. Patent Application No. 13/456,720, which I understand issued as U.S. Patent No. 8,927,592… time of the patented invention. I understand the relevant timeframe for the patented invention of …On Appeal from the United States Patent and Trademark Office, Patent Trial and Appeal Board | External link to document |
| 2020-06-12 | 4 | Patent/Trademark Report to Commissioner | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,583,110 B2. (myr) (Entered… 12 June 2020 1:20-cv-00804 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-07-31 | 62 | Amended Complaint | expiration of U.S. Patent Nos. 10,583,110 (“the ’110 patent”) and 10,716,777 (“the ’777 patent”). Case 1:20…regimen. 122. United States Patent No. 10,583,110 (copy attached as Exhibit A) is entitled…EACH DEFENDANT OF U.S. PATENT NO. 10,583,110 UNDER 35 U.S.C. § 271(e) …OF INFRINGEMENT OF U.S. PATENT NO. 10,583,110 UNDER 35 U.S.C. § 271(B) … FDA the patent number and expiration date of the ’777 patent and identified it as a patent “with respect | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
